Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Jul
01
Today In Oncology
Study Finds About One in Six Chemotherapy Drugs in Sub-Saharan Africa Fails Quality Tests
Partial-Breast Radiotherapy After Breast-Conserving Surgery: 10-Year Outcomes
Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper Tract Urothelial Carcinoma
Patterns of ICI Use and Survival Outcomes in Metastatic Colorectal Cancer
Genitourinary Oncology Highlights: Treatment Advances in Renal Cell, Bladder, Urothelial, and Prostate Cancers
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo